← Back to Clinical Trials
Recruiting NCT05773482

NCT05773482 Effects of Breathing and Attention Training (BAT) on Pain Modulation

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05773482
Status Recruiting
Phase
Sponsor University of Florida
Condition Fibromyalgia
Study Type INTERVENTIONAL
Enrollment 40 participants
Start Date 2023-04-03
Primary Completion 2027-03-09

Trial Parameters

Condition Fibromyalgia
Sponsor University of Florida
Study Type INTERVENTIONAL
Phase N/A
Enrollment 40
Sex ALL
Min Age 18 Years
Max Age 70 Years
Start Date 2023-04-03
Completion 2027-03-09
Interventions
Breathing and Attention Training (BAT)Breathing Control

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The hypersensitivity of fibromyalgia is associated with abnormal pain modulation within the CNS, but not with peripheral or central sensitization. Many brain areas that contribute to modulation of pain are known, but their testing is complex and expensive. Quantitative sensory testing is easier to perform and repeatable. Therefore, it will be used to evaluate the effects of Breathing Attention Training (BAT) on the hypersensitivity of FM participants. BAT is a form of mindfulness meditation shown to decrease FM symptoms and possibly pain sensitivity. We hypothesize that pain modulation of chronic pain patients is improved by BAT.

Eligibility Criteria

Inclusion Criteria: * Individuals diagnosed with fibromyalgia will have pain of duration \> 6 months and meeting the 1990 Research Diagnostic Criteria for FM (ACR) * Healthy, pain-free age matched controls without chronic pain Exclusion Criteria: * Personal or family history of photosensitive epilepsy * Prior history of cancer or diabetes * Patients must be willing to discontinue their analgesics, hypnotics, anxiolytics, or anti-depressants during the study period for at least 5 half-lives.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology